Paper32012154
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.
Ianevski A and 4 others. PLoS Comput Biol, 2020. Cited by 53 papers, by iCite.
Cite this record
ConductScience Library. SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. Papers, record 32012154. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32012154
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Antiviral Agents | Major topic |
| Drug Combinations | Major topic |
| Hemorrhagic Fever, Ebola | |
| High-Throughput Screening Assays | |
| Humans | |
| Neoplasms |
Source PubMed
References22
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31141631 | Ibrutinib and Venetoclax for First-Line Treatment of CLL. | N Engl J Med | 2019 | https://conductscience.org/library/papers/31141631 | PubMed |
| 2 | 28804127 | Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. | Leukemia | 2018 | https://conductscience.org/library/papers/28804127 | PubMed |
| 3 | 29483097 | Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. | Cancer Res | 2018 | https://conductscience.org/library/papers/29483097 | PubMed |
| 4 | 29245013 | Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. | Cell | 2017 | https://conductscience.org/library/papers/29245013 | PubMed |
| 5 | 27438145 | Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia. | Oncotarget | 2016 | https://conductscience.org/library/papers/27438145 | PubMed |
| 6 | 28379339 | SynergyFinder: a web application for analyzing drug combination dose-response matrix data. | Bioinformatics | 2017 | https://conductscience.org/library/papers/28379339 | PubMed |
| 7 | 27723879 | Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. | JAMA Intern Med | 2016 | https://conductscience.org/library/papers/27723879 | PubMed |
| 8 | 21532551 | Trial watch: Phase II failures: 2008-2010. | Nat Rev Drug Discov | 2011 | https://conductscience.org/library/papers/21532551 | PubMed |
| 9 | 27377132 | Combine and conquer: challenges for targeted therapy combinations in early phase trials. | Nat Rev Clin Oncol | 2017 | https://conductscience.org/library/papers/27377132 | PubMed |
| 10 | 29017371 | Cytarabine and daunorubicin for the treatment of acute myeloid leukemia. | Expert Opin Pharmacother | 2017 | https://conductscience.org/library/papers/29017371 | PubMed |
| 11 | 29939303 | Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. | J Infect Dis | 2018 | https://conductscience.org/library/papers/29939303 | PubMed |
| 12 | 26041706 | A screen of approved drugs and molecular probes identifies therapeutics with anti-Ebola virus activity. | Sci Transl Med | 2015 | https://conductscience.org/library/papers/26041706 | PubMed |
| 14 | 21576426 | Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21576426 | PubMed |
| 15 | 24898935 | Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. | Sci Rep | 2014 | https://conductscience.org/library/papers/24898935 | PubMed |
| 16 | 31432301 | Genome-wide off-targets of drugs: risks and opportunities. | Cell Biol Toxicol | 2019 | https://conductscience.org/library/papers/31432301 | PubMed |
| 17 | 27165605 | Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. | Mol Cancer | 2016 | https://conductscience.org/library/papers/27165605 | PubMed |
| 18 | 28104689 | Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma. | Blood | 2017 | https://conductscience.org/library/papers/28104689 | PubMed |
| 19 | 2692037 | What is synergy? | Pharmacol Rev | 1989 | https://conductscience.org/library/papers/2692037 | PubMed |
| 20 | 24085192 | A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | Toxicol Sci | 2014 | https://conductscience.org/library/papers/24085192 | PubMed |
| 21 | 26949479 | Searching for Drug Synergy in Complex Dose-Response Landscapes Using an Interaction Potency Model. | Comput Struct Biotechnol J | 2015 | https://conductscience.org/library/papers/26949479 | PubMed |
Cited by33
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42919347 | ComplexMatrixComb: predicting anticancer drug combination dosages for target growth inhibition via complex-number matrix factorization. | J Cheminform | 2026 | https://conductscience.org/library/papers/42919347 | PubMed |
| 42380246 | A review of deep learning approaches for drug synergy prediction in cancer. | NPJ Drug Discov | 2025 | https://conductscience.org/library/papers/42380246 | PubMed |
| 42307375 | Efficacy of selenium- and tellurium-based organocompounds against ruminant gastrointestinal nematodes in vitro. | Rev Bras Parasitol Vet | 2026 | https://conductscience.org/library/papers/42307375 | PubMed |
| 42185895 | Standardizing antiviral response metrics for mono- and combination therapies in acute, chronic and latent viral infections. | Virol J | 2026 | https://conductscience.org/library/papers/42185895 | PubMed |
| 42102151 | DeepDRP: Dose-response predictions of drug pairs using deep learning based on data-driven feature representation and dose-response curve characteristics. | PLoS One | 2026 | https://conductscience.org/library/papers/42102151 | PubMed |
| 41537239 | Characterizing clinical toxicity in cancer combination therapies. | Bioinformatics | 2026 | https://conductscience.org/library/papers/41537239 | PubMed |
| 41531664 | Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy. | Hemasphere | 2026 | https://conductscience.org/library/papers/41531664 | PubMed |
| 41397961 | An open-source screening platform accelerates discovery of drug combinations. | Nat Commun | 2025 | https://conductscience.org/library/papers/41397961 | PubMed |
| 40855143 | Preventing Preterm Birth: The Search for Tocolytic Synergism. | Reprod Sci | 2025 | https://conductscience.org/library/papers/40855143 | PubMed |
| 40234614 | Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia. | Leukemia | 2025 | https://conductscience.org/library/papers/40234614 | PubMed |
| 40186177 | Exome-wide association study reveals 7 functional variants associated with ex-vivo drug response in acute myeloid leukemia patients. | BMC Med Genomics | 2025 | https://conductscience.org/library/papers/40186177 | PubMed |
| 39323620 | Bioinformatics Approaches in the Development of Antifungal Therapeutics and Vaccines. | Curr Genomics | 2024 | https://conductscience.org/library/papers/39323620 | PubMed |
| 39261955 | Challenges in validation of combination treatment strategies for CRC using patient-derived organoids. | J Exp Clin Cancer Res | 2024 | https://conductscience.org/library/papers/39261955 | PubMed |
| 39168097 | A pan-cancer screen identifies drug combination benefit in cancer cell lines at the individual and population level. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/39168097 | PubMed |
| 38227161 | Network-based drug repurposing identifies small molecule drugs as immune checkpoint inhibitors for endometrial cancer. | Mol Divers | 2024 | https://conductscience.org/library/papers/38227161 | PubMed |
| 38214879 | Prolymphocytic Leukaemia: an Update on Biology and Treatment. | Curr Oncol Rep | 2024 | https://conductscience.org/library/papers/38214879 | PubMed |
| 38097586 | Mapping combinatorial drug effects to DNA damage response kinase inhibitors. | Nat Commun | 2023 | https://conductscience.org/library/papers/38097586 | PubMed |
| 37268740 | Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach. | Nat Rev Gastroenterol Hepatol | 2023 | https://conductscience.org/library/papers/37268740 | PubMed |
| 36733367 | Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia. | Front Oncol | 2022 | https://conductscience.org/library/papers/36733367 | PubMed |
| 36713829 | A comprehensive tool for tumor precision medicine with pharmaco-omics data analysis. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36713829 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| BCL2 | 596 | PubTator's text mining | https://conductscience.org/library/genes/596 | NCBI Gene |
| SLC25A6 | 293 | PubTator's text mining | https://conductscience.org/library/genes/293 | NCBI Gene |
| SYNM | 23336 | PubTator's text mining | https://conductscience.org/library/genes/23336 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32012154
GET https://conductscience.org/api/papers/v1/32012154/references?page=2